Tracers / [177Lu]Lu-RM2
[177Lu]Lu-RM2
Also written as RM2; [Lu-177]Lu-RM2; rm2; Rm2; rM2; Lu-177-RM2
- Radionuclide
- Lu-177 t½ 9584.6 min
- Modality
- Therapy
- Production route
- —
- Stage
- —
- Syntheses indexed
- 9
What it is
- Compound class
- GRPR-targeting peptide antagonist (DOTA-conjugated bombesin analog)
- Target / mechanism
- Gastrin-releasing peptide receptor (GRPR) antagonist PMID 38124121
- Clinical application
- —
- Theranostic pair
- <a href="/tracers/ga68-rm2/">ga68-rm2</a>
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| — | — | none | quantitative | more than 95% | RM2 | 40890559 2025 EJNMMI Res |
| — | — | none | quantitative | more than 95% | [Hse7]RM2 | 40890559 2025 EJNMMI Res |
| — | — | none | quantitative | more than 95% | [Bta8]RM2 | 40890559 2025 EJNMMI Res |
| Manual synthesis | — | — | over 90% | above 95% | RM2 | 39563828 2024 ACS Med Chem Lett [177Lu]LuCl3, Na–Ac buffer (400 nM), pH = 5.0, 98 °C, 25 min. — radiochemical yield was over 90% |
| — | — | — | — | — | RM2 | 38124121 2024 J Nucl Med |
| Manual synthesis | — | — | >98% | >97% | RM2 | 37584725 2023 Eur J Nucl Med Mol Imaging NeoB and RM2 were synthesized as described in Supplementary material 1. — [177Lu]Lu-NeoB and [177Lu]Lu-RM2 were obtained in > 98% RCY and > 97% RCP. |
| Manual synthesis | — | none | quantitative | >98% | RM2 | 35027371 2022 J Nucl Med 177Lu labeling of all compounds was performed manually — 177Lu labeling of all compounds was performed manually, each resulting in quantitative radiochemical yields |
| — | — | — | — | — | RM2 | 42429818 2026 Eur J Nucl Med Mol Imaging 161Tb- and 177Lu-Labeling was completed at 90 °C within 10 min (1.0 M sodium acetate buffer, pH = 5.5, molar activity of ~ 50 MBq/nmol) |
| — | — | — | — | — | — | 42301422 2026 Eur J Nucl Med Mol Imaging |
Need this precursor?We can point you to suppliers for [177Lu]Lu-RM2, or handle the enquiry for you.
Get in touchNotes
Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 7 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Diagnostic pair signal at discovery: YES - Ga-68, In-111. Compound class inferred from precursor name (not stated outright) -- PMID 38124121: 'RM2 (DOTA-Pip5-d-Phe6-Gln7-Trp8-Ala9-Val10-Gly11-His12-Sta13-Leu14-NH2)'.